Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata
Status:
Not yet recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
This study is a randomized, double-blind, placebo-controlled, multi-center, dose-ranging
study to characterize the efficacy and safety of BNZ-1 administered by slow IV push weekly
for 3 months to adults diagnosed with moderate to severe alopecia areata, defined as having a
>50% loss of terminal hair on the scalp. The study has three periods:
- 30-Day Screening Period
- 3-Month Treatment Period
- 3-Month Follow-up Period The study will be conducted at approximately 15-20 clinical
sites in the United States.